Trametinib

Small molecule

Also known as GSK1120212

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Melanoma, Glioma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • BRAF V600E Mutation-Positive Metastatic NSCLC MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see Dosage and Administration (2.1)] .
    Outside this platform's coverage
  • BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options [see Dosage and Administration (2.1)] .
    Outside this platform's coverage
  • BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors MEKINIST is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options [see Dosage and Administration (2.1)] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.6)] . Continued approval for this indication may be co
Product first approved 2013FDA label
EU
  • Mekinist (trametinib): initial indication BRAF V600 melanoma; later extended (with dabrafenib) to adjuvant melanoma, advanced NSCLC with BRAF V600 mutation and thyroid cancer
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
Melanoma
NCT02224781 · National Cancer Institute (NCI)
2015-09-08 – 2026-12-19 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
What this study did
NCT02967692 · Novartis Pharmaceuticals
2017-02-17 – 2024-08-21 · Melanoma
What this study did
NCT01682083 · Novartis Pharmaceuticals
2013-01-08 – 2023-07-31 · Melanoma
What this study did
NCT03551626 · Novartis Pharmaceuticals
2018-08-29 – 2021-09-16 · Malignant Melanoma
What this study did
NCT01584648 · Novartis Pharmaceuticals
2012-05-04 – 2019-02-28 · Melanoma
What this study did
NCT01245062 · GlaxoSmithKline
2010-11-22 – 2016-12-16 · Melanoma
What this study did
Other / comorbidity
NCT07817186 · Carelon Research
2027-08-01 – 2032-06-30 · HCM, Noonan Syndrome and Other Rasopathy, Heart Failure (Pediatric)
What this study did
NCT04940052 · Novartis Pharmaceuticals
2021-11-15 – 2027-05-25 · Differentiated Thyroid Cancer (DTC)
What this study did
NCT03784014 · Institut National de la Santé Et de la Recherche Médicale, France
2019-10-19 – 2026-01-20 · Soft Tissue Sarcoma
What this study did
Phase 2/3 (4)
Glioma
NCT07440290 · Cancer Research UK
2026-04-01 – 2029-10 · Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Gastrointestinal Cancer, Non-Melanoma Skin Cancer (NMSC), Langerhans Cell Histiocytosis (LCH), Cancer, Erdheim-Chester Disease, Thyroid Carcinoma, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small Cell-Lung, Glioma, Multiple Myeloma, Thyroid Carcinoma, Anaplastic, Solid Tumour, Pancreatic Diseases
What this study did
Other / comorbidity
NCT05722886 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Solid Tumour
What this study did
NCT06819605 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2025-03-01 – 2028-12-31 · Ameloblastoma
What this study did
NCT02101788 · National Cancer Institute (NCI)
2014-04-11 – 2025-10-27 · Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
What this study did
Phase 2 (118)
Glioma
NCT07110246 · University of California, San Francisco
2025-11-07 – 2032-03-31 · BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
What this study did
NCT05180825 · University Hospital, Strasbourg, France
2022-05-05 – 2031-12-01 · Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma
What this study did
NCT03919071 · National Cancer Institute (NCI)
2020-02-20 – 2027-09-30 · Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
What this study did
NCT03363217 · St. Justine's Hospital
2018-08-16 – 2027-03-01 · Low-grade Glioma, Plexiform Neurofibroma, Central Nervous System Glioma
What this study did
Melanoma
NCT03563729 · Inge Marie Svane
2018-06-06 – 2028-06-06 · Malignant Melanoma
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT02910700 · M.D. Anderson Cancer Center
2016-12-09 – 2027-12-08 · Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT02858921 · Melanoma Institute Australia
2017-11-08 – 2027-11 · Melanoma
What this study did
NCT01979523 · National Cancer Institute (NCI)
2013-11-21 – 2027-07-15 · Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
What this study did
NCT02231775 · M.D. Anderson Cancer Center
2014-10-22 – 2027-04-01 · Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
What this study did
NCT02196181 · National Cancer Institute (NCI)
2014-09-19 – 2027-03-15 · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT04417621 · Novartis Pharmaceuticals
2020-10-30 – 2027-02-02 · Melanoma
What this study did
NCT03149029 · Massachusetts General Hospital
2017-11-27 – 2026-12-31 · Metastatic Melanoma
What this study did
NCT01972347 · Melanoma Institute Australia
2014-10-01 – 2026-06-16 · Melanoma
What this study did
NCT02645149 · Melanoma Institute Australia
2021-11-22 – 2026-03-06 · Melanoma
What this study did
NCT04310397 · M.D. Anderson Cancer Center
2020-01-29 – 2023-10-09 · Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
What this study did
NCT04059224 · Universitair Ziekenhuis Brussel
2019-01-28 – 2023-06-30 · Stage IV Melanoma, Stage III Melanoma
What this study did
NCT02083354 · Novartis Pharmaceuticals
2014-03-18 – 2021-04-19 · Cancer, Melanoma
What this study did
NCT02296112 · Vanderbilt-Ingram Cancer Center
2015-01 – 2021-04-16 · Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
What this study did
NCT03352947 · Cambridge University Hospitals NHS Foundation Trust
2017-11-03 – 2020-11-27 · Melanoma
What this study did
NCT01726738 · UNC Lineberger Comprehensive Cancer Center
2013-04-04 – 2020-09-17 · Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
What this study did
NCT02974803 · Canadian Cancer Trials Group
2018-02-09 – 2020-07-29 · Melanoma, Brain Metastases
What this study did
NCT03972046 · TriHealth Inc.
2019-06-24 – 2020-02-03 · Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
What this study did
NCT02625337 · The Netherlands Cancer Institute
2016-01 – 2018-12 · Metastatic Melanoma
What this study did
NCT02410863 · Prof. Dr. med. Dirk Schadendorf
2015-11 – 2018-08 · Malignant Melanoma
What this study did
NCT02296996 · Universitair Ziekenhuis Brussel
2014-10 – 2017-12 · Malignant Melanoma
What this study did
NCT01941927 · Adil Daud
2013-09-10 – 2017-05-03 · Melanoma
What this study did
NCT01978236 · GlaxoSmithKline
2014-04-08 – 2017-04-26 · Melanoma and Brain Metastases
What this study did
NCT01721603 · University of California, San Francisco
2013-04 – 2016-01 · BRAFV600E Melanoma Patients
What this study did
NCT01701037 · Vanderbilt-Ingram Cancer Center
2013-01 – 2015-04 · Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
What this study did
NCT01328106 · GlaxoSmithKline
2010-11 – 2012-05 · GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT06563999 · Sun Yat-sen University
2024-11-01 – 2029-11-01 · Lung Cancer Stage III, Mutation
What this study did
NCT02642042 · National Cancer Institute (NCI)
2016-07-18 – 2027-03-03 · KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT06054191 · Sun Yat-sen University
2024-02-01 – 2027-03-01 · NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
What this study did
NCT04452877 · Novartis Pharmaceuticals
2020-08-19 – 2024-11-07 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03543306 · Asan Medical Center
2018-06-30 – 2022-06-30 · Cancer, Lung Cancer Metastatic, BRAF V600E
What this study did
NCT02672358 · Novartis Pharmaceuticals
2018-09-03 – 2020-12-07 · Non-Small-Cell Lung Cancer
What this study did
NCT03232892 · University of California, San Francisco
2018-02-13 – 2019-09-11 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06582745 · Cook Children's Health Care System
2024-06-24 – 2039-12 · Langerhans Cell Histiocytosis
What this study did
NCT04803318 · Second Affiliated Hospital of Guangzhou Medical University
2021-01-01 – 2037-01-01 · Solid Tumor, Adult, Hepatocellular Carcinoma
What this study did
NCT06119789 · Oslo University Hospital
2025-03-20 – 2036-08-01 · Rare Malignant Neoplasm
What this study did
Phase 1/2 (36)
Glioma
NCT06712875 · Ann & Robert H Lurie Children's Hospital of Chicago
2025-04-01 – 2029-06 · Low Grade Glioma, High Grade Glioma
What this study did
NCT04201457 · Pediatric Brain Tumor Consortium
2020-01-17 – 2026-12-31 · Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
What this study did
Melanoma
NCT01989585 · National Cancer Institute (NCI)
2014-03-24 – 2027-12-31 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
What this study did
NCT04557956 · National Cancer Institute (NCI)
2021-08-19 – 2027-03-11 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
What this study did
NCT05677373 · Alliance for Clinical Trials in Oncology
2023-01-13 – 2025-07-31 · Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma
What this study did
NCT02872259 · Haukeland University Hospital
2017-02-13 – 2024-05-23 · Melanoma
What this study did
NCT01902173 · National Cancer Institute (NCI)
2013-10-08 – 2023-12-23 · Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
What this study did
NCT03455764 · Dana-Farber Cancer Institute
2018-09-10 – 2023-09-05 · Melanoma
What this study did
NCT03754179 · Universitair Ziekenhuis Brussel
2018-01-23 – 2022-07-01 · Melanoma
What this study did
NCT02257424 · Abramson Cancer Center at Penn Medicine
2014-10 – 2021-10 · Advanced BRAF Mutant Melanoma
What this study did
NCT02130466 · Merck Sharp & Dohme LLC
2014-05-29 – 2021-07-14 · Melanoma, Solid Tumors
What this study did
NCT02392871 · Melanoma and Skin Cancer Trials Limited
2015-05 – 2020-04-17 · Metastatic Melanoma
What this study did
NCT02143050 · University of Louisville
2014-09 – 2017-11-17 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07468071 · Novartis Pharmaceuticals
2026-06-08 – 2029-09-11 · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
What this study did
NCT06456138 · Shanghai Chest Hospital
2024-07-01 – 2028-12-31 · KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
What this study did
NCT05275374 · Xynomic Pharmaceuticals, Inc.
2025-12-31 – 2028-12-30 · Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer, Thyroid Cancer, Nonsmall Cell Lung Cancer
What this study did
NCT05786924 · Institut de Recherches Internationales Servier
2023-04-18 – 2028-06 · Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
What this study did
NCT03225664 · M.D. Anderson Cancer Center
2018-02-03 – 2027-12-31 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT05358249 · Novartis Pharmaceuticals
2022-10-24 – 2026-09-28 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
What this study did
NCT03704688 · Memorial Sloan Kettering Cancer Center
2018-10-09 – 2022-02-04 · Non Small Cell Lung Cancer, KRAS Gene Mutation
What this study did
NCT03076164 · Memorial Sloan Kettering Cancer Center
2017-03-01 – 2020-12-18 · Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV, Recurrent Lung Adenocarcinoma, Recurrent Lung Cancer
What this study did
NCT02230553 · The Netherlands Cancer Institute
2014-10-07 – 2019-08-06 · Colorectal Cancer
What this study did
NCT02580708 · Clovis Oncology, Inc.
2015-09-30 – 2016-06-27 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05849662 · Therapeutic Advances in Childhood Leukemia Consortium
2024-10-11 – 2029-12 · Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL Syndrome
What this study did
NCT05658640 · Princess Maxima Center for Pediatric Oncology
2023-11-14 – 2029-04-01 · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
What this study did
NCT05874414 · Genfit
2023-08-21 – 2028-06 · Cholangiocarcinoma
What this study did
NCT07890701 · Second Affiliated Hospital of Wenzhou Medical University
2026-10-20 – 2027-11-01 · Histiocytosis,Langerhans-Cell
What this study did
NCT07072403 · West China Hospital
2025-07-07 – 2027-09-01 · Vascular Anomalies
What this study did
NCT02079740 · National Cancer Institute (NCI)
2014-03-26 – 2027-03-09 · Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
What this study did
NCT03377361 · Bristol-Myers Squibb
2018-01-31 – 2024-11-04 · Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
What this study did
NCT04326283 · Genuv Inc.
2020-04-02 – 2023-04-28 · Amyotrophic Lateral Sclerosis
What this study did
NCT05071183 · Turning Point Therapeutics, Inc.
2021-09-23 – 2023-03-01 · KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
What this study did
NCT01750918 · Novartis Pharmaceuticals
2012-12-19 – 2020-06-18 · Cancer
What this study did
Phase 1 (85)
Glioma
NCT04485559 · University of California, San Francisco
2020-12-09 – 2027-12-31 · Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
What this study did
NCT03434262 · St. Jude Children's Research Hospital
2018-03-05 – 2024-05-24 · Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
What this study did
Melanoma
NCT04903119 · Rina Plattner
2022-06-01 – 2030-06-01 · Metastatic Melanoma, BRAF Gene Mutation
What this study did
NCT03026517 · Memorial Sloan Kettering Cancer Center
2017-01 – 2025-01-21 · Melanoma
What this study did
NCT03501368 · H. Lee Moffitt Cancer Center and Research Institute
2018-06-27 – 2024-12-30 · Melanoma, Unresectable Melanoma, Advanced Melanoma
What this study did
NCT02097225 · National Cancer Institute (NCI)
2014-05-29 – 2022-10-26 · BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
What this study did
NCT01940809 · National Cancer Institute (NCI)
2013-08-28 – 2022-03-04 · BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT02382549 · Craig L Slingluff, Jr
2016-04 – 2022-02-28 · Melanoma
What this study did
NCT03088176 · West Cancer Center
2017-06-25 – 2021-06-30 · Melanoma, BRAF Gene Mutation
What this study did
NCT03272464 · Massachusetts General Hospital
2019-05-29 – 2019-12-27 · Melanoma
What this study did
NCT02110355 · Kartos Therapeutics, Inc.
2014-12-19 – 2018-12-27 · Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma
What this study did
NCT02027961 · MedImmune LLC
2013-12-20 – 2018-04-24 · Melanoma
What this study did
NCT02915666 · University of Texas Southwestern Medical Center
2016-10 – 2017-07-17 · Melanoma
What this study did
NCT02138292 · University of Texas Southwestern Medical Center
2014-07 – 2017-02-23 · Melanoma
What this study did
NCT02300935 · SCRI Development Innovations, LLC
2015-12 – 2016-01-20 · Melanoma
What this study did
NCT01767454 · GlaxoSmithKline
2013-02-12 – 2015-09-04 · Solid Tumours
What this study did
NCT02357732 · University of Pittsburgh
2015-08 – 2015-08 · Metastatic Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT03333343 · Novartis Pharmaceuticals
2018-01-29 – 2027-07-12 · EGFR-mutant Non-small Cell Lung Cancer
What this study did
NCT04892017 · Deciphera Pharmaceuticals, LLC
2021-06-15 – 2026-03-30 · Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT05668585 · C4 Therapeutics, Inc.
2022-12-08 – 2025-11-05 · Solid Tumors, Melanoma, NSCLC, CRC, ATC
What this study did
NCT03299088 · Jonathan Riess
2018-06-26 – 2024-06-25 · KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT05435846 · Collin Blakely
2022-08-10 – 2024-05-31 · Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
What this study did
NCT02974725 · Novartis Pharmaceuticals
2017-02-24 – 2024-04-24 · Non-Small Cell Lung Cancer, Melanoma
What this study did
NCT04967079 · Shanghai Chest Hospital
2021-08-01 – 2024-03-26 · Non Small Cell Lung Cancer
What this study did
NCT03516214 · University of Cologne
2018-04-25 – 2023-11-27 · Bronchial Neoplasms
What this study did
NCT01912625 · National Cancer Institute (NCI)
2013-10-28 – 2023-02-24 · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT03087448 · University of California, San Francisco
2017-09-09 – 2022-04-30 · Non-small Cell Lung Cancer
What this study did
NCT02900664 · Novartis Pharmaceuticals
2016-08-23 – 2021-03-17 · Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
What this study did
NCT02258607 · Sierra Oncology LLC - a GSK company
2015-03-11 – 2017-02-27 · Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
What this study did
NCT02538627 · Merrimack Pharmaceuticals
2015-08 – 2016-10-05 · Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01938456 · GlaxoSmithKline
2013-10 – 2014-07 · Lung Cancer, Non-Small Cell
What this study did
Other / comorbidity
NCT03631953 · Assistance Publique Hopitaux De Marseille
2019-09-30 – 2028-12-30 · Meningioma
What this study did
NCT06962254 · China Medical University Hospital
2025-05-10 – 2028-03-31 · Solid Tumor Cancer
What this study did
NCT04185883 · Amgen
2019-12-17 – 2027-12-05 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
What this study did
NCT03975231 · City of Hope Medical Center
2020-09-14 – 2027-10-05 · BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
What this study did
NCT02015117 · National Cancer Institute (NCI)
2014-04-28 – 2027-09-23 · Metastatic Malignant Neoplasm in the Brain
What this study did
NCT03085056 · Memorial Sloan Kettering Cancer Center
2017-03-15 – 2027-09 · Anaplastic Thyroid Cancer
What this study did
NCT06804824 · Vividion Therapeutics, Inc.
2025-02-25 – 2027-08-01 · Advanced Solid Tumors
What this study did
NCT04111458 · Boehringer Ingelheim
2019-11-04 – 2027-04-30 · Solid Tumors, KRAS Mutation; SOS1
What this study did
NCT05907304 · Erasca, Inc.
2023-08-17 – 2026-12 · Advanced or Metastatic Solid Tumors
What this study did
NCT03091257 · Massachusetts General Hospital
2017-06-21 – 2026-09-15 · Multiple Myeloma
What this study did
NCT03065387 · M.D. Anderson Cancer Center
2017-10-31 – 2026-04-23 · Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
What this study did
NCT06902792 · Second Affiliated Hospital of Wenzhou Medical University
2025-02-06 – 2026-02-02 · Histiocytosis, Langerhans-Cell
What this study did
NCT04454476 · Vanderbilt-Ingram Cancer Center
2022-11-09 – 2025-12 · Gastric Cancer, Metaplasia, Stage I Gastric Cancer, Initial-onset Gastric Cancer
What this study did
NCT03825289 · University of Utah
2019-01-30 – 2025-08-03 · Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
What this study did
NCT04965220 · Shanghai Henlius Biotech
2022-01-05 – 2025-06-30 · Solid Tumor
What this study did
NCT05440942 · Peter Hosein, MD
2023-01-19 – 2025-05-30 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT02070549 · National Cancer Institute (NCI)
2014-03-10 – 2024-12-18 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
What this study did
NCT04294160 · Novartis Pharmaceuticals
2020-07-22 – 2024-09-25 · BRAF V600 Colorectal Cancer
What this study did
Phase 4 (4)
Glioma
NCT03975829 · Novartis Pharmaceuticals
2019-11-04 – 2026-11-05 · Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
What this study did
Non-Small Cell Lung Cancer
NCT03340506 · Novartis Pharmaceuticals
2018-01-26 – 2032-12-28 · Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
What this study did
Other / comorbidity
NCT07010393 · Fujian Medical University
2025-07-01 – 2028-12-31 · Thyroid Neoplasms
What this study did
NCT06195228 · Fudan University
2020-01-01 – 2028-12-31 · Advanced Thyroid Cancer Patients Who Received Target Therapy
What this study did
Early phase / not applicable (3)
Melanoma
NCT03979651 · Hospices Civils de Lyon
2019-10-15 – 2023-01-03 · Metastatic NRAS Melanoma
What this study did
Other / comorbidity
NCT07131059 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-11 – 2028-10-30 · AML, Adult
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT06475989 · ECOG-ACRIN Cancer Research Group
2024-12-27 – 2030-09-30 · Refractory Differentiated Thyroid Gland Carcinoma
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Melanoma
NCT06346067 · Erasca, Inc.
2024-04-29 – 2028-12 · Advanced or Metastatic NRAS-mutant Melanoma
What this study did
Phase 2 (1)
Melanoma
NCT04527549 · ECOG-ACRIN Cancer Research Group
2021-06-01 – 2024-01-08 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Melanoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trametinib: this drugApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(58 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trametinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 2Ameloblastoma, BRAF V600E Mutation PositiveRecruiting
Est. primary completion 2026-12-31 · NCT06653517 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 4Advanced Thyroid Cancer Patients Who Received Target TherapyRecruiting
Est. primary completion 2026-12-31 · NCT06195228 · CT.gov ↗
What to watch
2027 (29)
January 2027 (2)
Phase 2Anaplastic Thyroid CancerRecruiting
Est. primary completion 2027-01-01 · NCT06079333 · CT.gov ↗
What to watch
Phase 2EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma …Active not recruiting
Est. primary completion 2027-01-31 · NCT03087071 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-02-02 · NCT04417621 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2GliomaActive not recruiting
Est. primary completion 2027-03-01 · NCT03363217 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-03-15 · NCT02196181 · CT.gov ↗
What to watch
Phase 1Solid Tumors, KRAS Mutation; SOS1Active not recruiting
Est. primary completion 2027-03-31 · NCT04111458 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-04-01 · NCT02231775 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related TumorsActive not recruiting
Est. primary completion 2027-06-20 · NCT04238624 · CT.gov ↗
What to watch
Phase 2HistiocytosisActive not recruiting
Est. primary completion 2027-06-30 · NCT04943224 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1/2Vascular AnomaliesActive not recruiting
Est. primary completion 2027-07-01 · NCT07072403 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-12 · NCT03333343 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-08-01 · NCT06804824 · CT.gov ↗
What to watch
September 2027 (5)
Phase 1Anaplastic Thyroid CancerActive not recruiting
Est. primary completion 2027-09 · NCT03085056 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor …Active not recruiting
Est. primary completion 2027-09-02 · NCT04544111 · CT.gov ↗
What to watch
Phase 2CraniopharyngiomaRecruiting
Est. primary completion 2027-09-10 · NCT05525273 · CT.gov ↗
What to watch
Phase 2GliomaActive not recruiting
Est. primary completion 2027-09-30 · NCT03919071 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Histiocytosis,Langerhans-CellEnrolling by invitation
Est. primary completion 2027-10-01 · NCT07890701 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06563999 · CT.gov ↗
What to watch
Phase 2NeoplasmsActive not recruiting
Est. primary completion 2027-11-10 · NCT06967155 · CT.gov ↗
What to watch
December 2027 (9)
Phase 1/2CholangiocarcinomaRecruiting
Est. primary completion 2027-12 · NCT05874414 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT05275374 · CT.gov ↗
What to watch
Phase 1GliomaRecruiting
Est. primary completion 2027-12-31 · NCT04485559 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT03225664 · CT.gov ↗
What to watch
Phase 1/2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT01989585 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
2028 (10)
March 2028 (2)
Phase 2Osteosarcoma, MetastasisRecruiting
Est. primary completion 2028-03 · NCT07477457 · CT.gov ↗
What to watch
Phase 1Solid Tumor CancerRecruiting
Est. primary completion 2028-03-31 · NCT06962254 · CT.gov ↗
What to watch
May 2028 (1)
Early phase / not applicableAML, AdultRecruiting
Est. primary completion 2028-05-10 · NCT07131059 · CT.gov ↗
What to watch
June 2028 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06 · NCT05786924 · CT.gov ↗
What to watch
Phase 2Langerhans Cell Histiocytosis (LCH)Recruiting
Est. primary completion 2028-06-01 · NCT07022834 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2028-07-01 · NCT04903119 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-10-30 · NCT04675710 · CT.gov ↗
What to watch
Phase 2/3AmeloblastomaNot yet recruiting
Est. primary completion 2028-10-30 · NCT06819605 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2GliomaRecruiting
Est. primary completion 2028-12 · NCT06712875 · CT.gov ↗
What to watch
Phase 1/2Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL SyndromeRecruiting
Est. primary completion 2028-12 · NCT05849662 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
Phase 2Solid Tumor, Adult, Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01-01 · NCT04803318 · CT.gov ↗
What to watch
April 2029 (2)
Phase 1/2Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …Recruiting
Est. primary completion 2029-04-01 · NCT05658640 · CT.gov ↗
What to watch
Phase 2Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid CarcinomaNot yet recruiting
Est. primary completion 2029-04-08 · NCT07886905 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-06-11 · NCT07468071 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
October 2029 (3)
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
Phase 2/3GliomaRecruiting
Est. primary completion 2029-10 · NCT07440290 · CT.gov ↗
What to watch
Phase 2Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies, Vascular AnomalyRecruiting
Est. primary completion 2029-10-27 · NCT07549646 · CT.gov ↗
What to watch
2031 (2)
November 2031 (2)
Phase 2GliomaRecruiting
Est. primary completion 2031-11-01 · NCT05180825 · CT.gov ↗
What to watch
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch
2032 (3)
March 2032 (1)
Phase 2GliomaRecruiting
Est. primary completion 2032-03-31 · NCT07110246 · CT.gov ↗
What to watch
June 2032 (1)
Phase 3HCM, Noonan Syndrome and Other Rasopathy, Heart Failure (Pediatric)Not yet recruiting
Est. primary completion 2032-06-30 · NCT07817186 · CT.gov ↗
What to watch
December 2032 (1)
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-12-28 · NCT03340506 · CT.gov ↗
What to watch
2033 (1)
November 2033 (1)
Phase 2Rare Malignant NeoplasmRecruiting
Est. primary completion 2033-11-30 · NCT06119789 · CT.gov ↗
What to watch
2039 (1)
June 2039 (1)
Phase 2Langerhans Cell HistiocytosisRecruiting
Est. primary completion 2039-06 · NCT06582745 · CT.gov ↗
What to watch

See the full readout calendar ↗